Eli Lilly and Company (NYSE:LLY) Shares Acquired Rep. Jonathan L. Jackson

Representative Jonathan L. Jackson (D-Illinois) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on May 13th, the Representative disclosed that they had bought between $15,001 and $50,000 in Eli Lilly and Company stock on April 21st. The trade occurred in the Representative’s “MORGAN STANLEY TRUST ACCOUNT” account.

Representative Jonathan L. Jackson also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 4/21/2025.
• Purchased $50,001 – $100,000 in shares of Netflix (NASDAQ:NFLX) on 4/16/2025.
• Sold $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 4/16/2025.
• Sold $15,001 – $50,000 in shares of Aramark (NYSE:ARMK) on 4/10/2025.
• Sold $50,001 – $100,000 in shares of Microsoft (NASDAQ:MSFT) on 4/10/2025.
• Sold $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 3/11/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 3/4/2025.

Eli Lilly and Company Trading Down 4.0%

LLY opened at $716.19 on Thursday. The stock has a market capitalization of $678.76 billion, a P/E ratio of 61.16, a P/E/G ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm’s fifty day simple moving average is $801.10 and its 200 day simple moving average is $808.28. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company’s revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.58 earnings per share. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.84%. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of the company. RMR Wealth Builders grew its stake in Eli Lilly and Company by 2.3% in the 4th quarter. RMR Wealth Builders now owns 4,686 shares of the company’s stock valued at $3,618,000 after buying an additional 107 shares during the last quarter. Czech National Bank grew its stake in Eli Lilly and Company by 6.3% in the 4th quarter. Czech National Bank now owns 170,840 shares of the company’s stock valued at $131,888,000 after buying an additional 10,143 shares during the last quarter. Aprio Wealth Management LLC grew its stake in Eli Lilly and Company by 10.8% in the 4th quarter. Aprio Wealth Management LLC now owns 2,627 shares of the company’s stock valued at $2,028,000 after buying an additional 257 shares during the last quarter. Matrix Trust Co acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $164,000. Finally, City Center Advisors LLC grew its stake in Eli Lilly and Company by 5.4% in the 4th quarter. City Center Advisors LLC now owns 565 shares of the company’s stock valued at $436,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Citigroup cut their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is owned by company insiders.

About Representative Jackson

Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois’ 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois’ 1st Congressional District. He declared candidacy for the 2026 election.

Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson’s career experience includes working as an investment analyst and an entrepreneur.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.